Nishant’s practice focuses on corporate and securities law matters. Nishant routinely advises issuers, investors, and investment banking firms on a variety of transactions, with a focus on initial public offerings, follow-on offerings, private investments in public equity (PIPEs), registered direct offerings, SPACs, and mergers and acquisitions.

Nishant also provides counsel to public and private companies on corporate governance, SEC reporting and disclosure requirements, compliance matters and stock exchange requirements. Nishant advises clients in a wide range of industries, including health care, life sciences, medical device, technology, and energy and sustainability.

Select Initial Public Offering Representations

ArriVent BioPharma, Inc. in its $200 million initial public offering.
Viela Bio, Inc. in its $172.5 million initial public offering.
Cowen and Company as lead underwriter in Praxis Precision Medicines, Inc.’s $218 million initial public offering.
G1 Therapeutics, Inc. in its $121 million initial public offering.
Sera Prognostics, Inc. in its $80 million initial public offering.

Select Follow-On Offering & Alternate Transaction Representations

Viela Bio, Inc. in its $170 million follow-on offering.
Goldman Sachs as lead underwriter in Fulcrum Therapeutics, Inc.’s $143 million follow-on offering and $75 million follow-on offering.
Leerink Partners as lead underwriter in MoonLake Immunotherapeutics' $460 million follow-on offering.
Piper Sandler as lead underwriter in Praxis Precision Medicines, Inc.’s $172 million follow-on offering.
Aspen Aerogels, Inc. in its $275 million follow-on offering and its $75 million registered direct offering.
Aspen Aerogels, Inc. in a $100 million Convertible Note PIPE with an affiliate of Koch Strategic Platforms, LLC.
Synlogic, Inc. in multiple follow-on offerings raising aggregate proceeds of $180 million.
Aspen Aerogels, Inc. in $125 million common stock PIPEs with an affiliate of Koch Strategic Platforms, LLC.
J.P. Morgan as lead underwriter in Acceleron Pharma Inc.’s $230 million follow-on offering.
Cowen and Company as lead underwriter in Rocket Pharmaceuticals, Inc.’s $85 million follow-on offering.
Truist Securities as sole placement agent in Verastem Oncology, Inc.’s $60 million Series B Convertible Preferred Stock PIPE.
William Blair & Company as sole placement agent in Vapotherm, Inc.’s $23 million PIPE.
Leerink Partners as lead underwriter in ArQule, Inc.’s $65 million follow-on offering.

Select Mergers & Acquisitions Representations

Viela Bio, Inc. in its $3.05 billion sale to Horizon Therapeutics, Inc.
NET Power, Inc. in a business combination / de-SPAC to create a combined company valued at $1.5 billion.
Elicio Therapeutics, Inc. in its reverse merger with Angion BioMedica Corp.
Molecular Templates, Inc. in its reverse merger with Threshold Pharmaceuticals, Inc.
Synta Pharmaceuticals Corp. in its reverse merger with Madrigal Pharmaceuticals, Inc.
Seventh Generation, Inc. in its sale to Unilever.
Presence Learning, Inc. in its acquisition of Global Therapy and a concurrent majority investment from Spectrum Equity, and The Rise Fund, TPG’s multisector global impact investment strategy.

Read less